These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2936143)

  • 1. Renal effects of cyclooxygenase and thromboxane synthetase inhibitors in dogs with experimental liver disease and in rats with glomerulonephritis.
    Dunn MJ; Zambraski E; Lianos E; Stork J
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():465-8. PubMed ID: 2936143
    [No Abstract]   [Full Text] [Related]  

  • 2. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
    Gorman RR
    Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
    [No Abstract]   [Full Text] [Related]  

  • 3. Five-to-seven-day kidney preservation with aspirin and furegrelate.
    Schilling M; Saunder A; Southard JH; Belzer FO
    Transplantation; 1993 Apr; 55(4):955-8. PubMed ID: 8475574
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of cyclooxygenase and thromboxane synthase inhibition on the response to angiotensin II in the hypoperfused canine kidney.
    Goto F; Jackson EK; Ohnishi A; Herzer W; Branch RA
    J Pharmacol Exp Ther; 1987 Dec; 243(3):799-803. PubMed ID: 3121844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological manipulation of canine cyclooxygenase and thromboxane synthetase in vivo: differential renal and platelet recovery rates.
    Oshima T; McCluskey ER; Honda A; Needleman P
    J Pharmacol Exp Ther; 1984 May; 229(2):598-602. PubMed ID: 6425495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematologic effects of prostaglandins and thromboxanes and inhibitors of their synthesis in the perinatal period.
    Friedman Z; Berman W
    Semin Perinatol; 1980 Jan; 4(1):73-84. PubMed ID: 6770470
    [No Abstract]   [Full Text] [Related]  

  • 7. Tissue-selective inhibition of prostaglandin and thromboxane synthesis in man: investigative and therapeutic implications.
    Patrono C
    Clin Physiol; 1984 Dec; 4(6):443-7. PubMed ID: 6440732
    [No Abstract]   [Full Text] [Related]  

  • 8. Thromboxane synthetase inhibitors, thromboxane receptor antagonists, and aspirin in cardiovascular disease.
    Dorn GW; Halushka PV
    Ration Drug Ther; 1985 Jul; 19(7):1-7. PubMed ID: 2997839
    [No Abstract]   [Full Text] [Related]  

  • 9. Can the effects of protein restriction on the progression of renal failure also be achieved by pharmacological means?
    Verberckmoes R; Van Renterghem Y
    Blood Purif; 1989; 7(1):58-60. PubMed ID: 2493259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanism of action of antiplatelet medication].
    Navarro JL; Frade FJ; Alava I; Obispo T; Trejo R; Jiménez C; Cesar J
    Sangre (Barc); 1984; 29(4-C):817-32. PubMed ID: 6096974
    [No Abstract]   [Full Text] [Related]  

  • 11. Hemodynamic roles of thromboxane A2 and prostaglandin E2 in glomerulonephritis.
    Stork JE; Dunn MJ
    J Pharmacol Exp Ther; 1985 Jun; 233(3):672-8. PubMed ID: 3859644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal effects of nonsteroidal anti-inflammatory agents.
    Lifschitz MD
    J Lab Clin Med; 1983 Sep; 102(3):313-23. PubMed ID: 6411840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dietary n-3 fatty acid supplementation versus thromboxane synthetase inhibition on gentamicin-induced nephrotoxicosis in healthy male dogs.
    Grauer GF; Greco DS; Behrend EN; Fettman MJ; Mani I; Getzy DM; Reinhart GA
    Am J Vet Res; 1996 Jun; 57(6):948-56. PubMed ID: 8725828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
    Aiken JW; Shebuski RJ; Miller OV; Gorman RR
    J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity.
    Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A
    J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelium-dependent vasorelaxation induced by L-carnitine in isolated aorta from normotensive and hypertensive rats.
    Herrera MD; Bueno R; De Sotomayor MA; Pérez-Guerrero C; Vázquez CM; Marhuenda E
    J Pharm Pharmacol; 2002 Oct; 54(10):1423-7. PubMed ID: 12396307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eicosanoids in experimental and human renal disease.
    Stork JE; Rahman MA; Dunn MJ
    Am J Med; 1986 Jan; 80(1A):34-45. PubMed ID: 3080878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a thromboxane synthetase inhibitor on eicosanoid synthesis and glomerular injury during acute unilateral glomerulonephritis in the rat.
    Cook HT; Cattell V; Smith J; Salmon JA; Moncada S
    Clin Nephrol; 1986 Oct; 26(4):195-202. PubMed ID: 3490944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of membranoproliferative glomerulonephritis and nephrotic syndrome in a dog with a thromboxane synthetase inhibitor.
    Grauer GF; Frisbie DD; Snyder PS; Dubielzig RR; Panciera DL
    J Vet Intern Med; 1992; 6(2):77-81. PubMed ID: 1588545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs, prostaglandins, and renal function.
    Patrono C; Ciabattoni G; Filabozzi P; Catella F; Forni L; Segni M; Patrignani P; Pugliese F; Simonetti BM; Pierucci A
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():131-9. PubMed ID: 2988308
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.